| |
For researchers unaffiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing or sharing them can be even harder. Can a new tool address this gap? Learn more.
|
|
Today's Big NewsDec 8, 2022 |
| By Annalee Armstrong Novartis is hoping to be appointed leader in a rare blood disease, and the latest data that iptacopan increases hemoglobin levels in patients with a disease called paroxysmal nocturnal hemoglobinuria should help. |
|
|
|
By Nick Paul Taylor Vertex has opened another front in its attempt to treat a rare cause of muscle weakness, paying Entrada Therapeutics $224 million upfront for the preclinical prospect ENTR-701. |
By Max Bayer Back in 2018, Revolution Medicines launched its SHP2 inhibitor with a splash thanks to a $550 million licensing deal with Sanofi. But, after four years, Sanofi is docking the deal. |
By Nick Paul Taylor In a statement that calls the results “implausible” four times, and “unplausible” once, Relmada made the case that its RELIANCE I study was undone by data from two high-enrolling sites. |
|
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by preemptively demonstrating low risk data. Learn how to leverage your data to maximize value: Read More >>
|
|
By Max Bayer Instil Bio is looking to install a new path forward, culling its lead asset and laying off 60% of its staff. But dosing remains paused in the phase 1 trial of the company's now-sole clinical-stage med. |
By Gabrielle Masson As the FDA prepares updated guidance on ways to boost clinical diversity for research trials, the agency’s head is urging administrators to prioritize the issue. |
By Annalee Armstrong PwC is out today with its annual rundown of deals to date and what’s to come in the year ahead, finding that life sciences M&A volume was down by 48% this year while valuations plunged 28%. |
By Max Bayer Following President Joe Biden's cancer initiative, European organizations are launching a moonshot of their own aimed at rare diseases. A coalition of seven European organizations hopes to accelerate the development of new therapies and improve clinical trials. |
By Joseph Keenan Florida-based CRO Sitero is partnering with healthcare technology firm CRIO to help streamline clinical trial data that can bog down sites and sponsors. |
By Andrea Park Ramesh “Sunny” Balwani was sentenced to nearly 13 years in prison for the part he played in defrauding investors and patients while helping lead blood testing startup Theranos, a federal judge ruled Wednesday. |
By Kevin Dunleavy The odd saga of Oncopeptides' multiple myeloma drug—thriving in Europe while sidelined in the U.S.—continued Wednesday with the FDA requesting a withdrawal of the U.S. marketing authorization for Pepaxto. |
By Heather Landi Amazon will no longer support HIPAA compliance on its Alexa devices after launching a program three years ago for some hospitals and payers. |
By Fraiser Kansteiner Plaintiffs in the now-dismissed clutch of cases argued Merck's vaccine Zostavax caused their shingles. But the medical expert attempting to back up that claim failed to consider whether plaintiffs’ disease occurred naturally because they’d had chickenpox as kids, according to court filings published this week. |
By Andrea Park More than a year into its patent dispute with Apple over the heart-monitoring technology embedded in the tech giant’s eponymous smartwatch, AliveCor has been dealt a serious blow. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the current state of Biogen and recent investor reactions to the new hire. Plus we cover the week's news including: What Albert Bourla said that has him in hot water, a $3.5 million drug, and we tease a possible major acquisition. |
|
|---|
|
|
|
Thursday, December 15, 2022 | 11am ET / 8am PT Cell therapy products have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. In this webinar we discuss what these key challenges are, how to approach these challenges and some opportunities available to better the process. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
| WhitepaperLearn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
